DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Pemetrexed
Procedure: Surgery

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 52

Registration Number: NCT00226577

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Radiation

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT00226590

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida, United States

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Vinorelbine
Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2005-09-22

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 53

Registration Number: NCT00215930

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: zoledronic acid
Drug: vincristine
Drug: dexamethasone
Drug: adriamycin
Drug: thalidomide

First Posted Date: 2005-09-22

Last Posted Date: 2014-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 90

Registration Number: NCT00215943

Locations: 🇺🇸
Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸
Fawcett Memorial Hospital, Port Charlotte, Florida, United States
🇺🇸
Watson Clinic, Lakeland, Florida, United States

and more 2 locations

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Phase 2

Terminated

Conditions: Esophageal Adenocarcinomas
Adenocarcinomas of the Gastroesophageal Junction

First Posted Date: 2005-09-22

Last Posted Date: 2013-11-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT00216008

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

Phase 1

Completed

Conditions: Rectal Neoplasms

Interventions: Drug: topotecan
Procedure: radiation
Procedure: surgery

First Posted Date: 2005-09-22

Last Posted Date: 2013-12-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 31

Registration Number: NCT00215956

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2005-09-22

Last Posted Date: 2013-11-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT00215982

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷
San Juan Veterans Hospital, Rio Piedras, Puerto Rico

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Cisplatin
Drug: Irinotecan
Drug: ZD 1839

First Posted Date: 2005-09-22

Last Posted Date: 2012-01-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT00215995

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷
Ponce School of Medicine, Ponce, Puerto Rico
🇵🇷
University of Puetro Rico Cancer Center, San Juan, Puerto Rico

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Phase 2

Terminated

Conditions: Colon Cancer
Adenocarcinoma

Interventions: Drug: XELOX
Drug: XELIRI
Drug: Bevacizumab

First Posted Date: 2005-08-05

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 65

Registration Number: NCT00127036

Locations: 🇺🇸
St. Joseph's Candler Health System, Savannah, Georgia, United States
🇺🇸
Bay Area Oncology, Tampa, Florida, United States
🇺🇸
Fawcett Memorial Hospital, Port Charlotte, Florida, United States

and more 9 locations

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Not Applicable

Terminated

Conditions: Lung Cancer

Interventions: Drug: ZD1839

First Posted Date: 2005-03-04

Last Posted Date: 2012-10-31

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT00104728

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy